Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29724793 | 1.00 | ROCK2 (0.40) | ROCK2FGFR4KCNH2VNN1HDAC3 | |
| SCHEMBL29724839 | 0.85 | HDAC3 (0.49) | KCNH2VNN1HDAC3HDAC1HDAC2 | |
| SCHEMBL14936917 | 0.85 | HDAC3 (0.49) | KCNH2VNN1HDAC3HDAC1HDAC2 | |
| SCHEMBL12288024 | 0.83 | PDE4B (0.42) | FGFR4KCNH2VNN1HDAC3HDAC1 | |
| SCHEMBL29725003 | 0.83 | PDE4B (0.42) | FGFR4KCNH2VNN1HDAC3HDAC1 | |
| SCHEMBL12288588 | 0.82 | HDAC3 (0.34) | ROCK2HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL14936829 | 0.82 | ROCK2 (0.39) | ROCK2HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL19942160 | 0.82 | ROCK2 (0.33) | ROCK2HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL12294258 | 0.81 | KCNH2 (0.39) | FGFR4KCNH2VNN1HDAC3HDAC1 | |
| SCHEMBL12288593 | 0.81 | NPC1 (0.39) | ROCK2HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11369565-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11369565-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20210045997-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210045997-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | CYTOKINETICS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10765624-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10765624-B2 | Amino-pyrimidine skeletal muscle modulators | CYTOKINETICS, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| EP-3698795-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | Cytokinetics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3698795-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | Cytokinetics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-8962632-B2 | Certain amino-pyrimidines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962632-B2 | Certain amino-pyrimidines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962632-B2 | Certain amino-pyrimidines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140206709-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2014-07-24 | — | — | US | disclosed |
| US-20140206709-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2014-07-24 | — | — | US | disclosed |
| US-20140206709-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. | 2014-07-24 | — | — | US | disclosed |
| US-20130123289-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123289-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123289-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2011133888-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11369565-B2 | Amino-pyrimidine skeletal muscle modulators | MUSK, PYGM, TNNC1 | ROCK2 3315/4885FGFR4 2840/4885KCNH2 3055/4885 |
| US-10765624-B2 | Amino-pyrimidine skeletal muscle modulators | MUSK, PYGM, TNNC1 | ROCK2 3066/4885FGFR4 1740/4885KCNH2 3128/4885 |
| US-20230026651-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | MUSK, PYGM, TNNC1 | ROCK2 3066/4885FGFR4 1740/4885KCNH2 3128/4885 |
| US-20210045997-A1 | AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS | MUSK, PYGM, TNNC1 | ROCK2 3315/4885FGFR4 2840/4885KCNH2 3055/4885 |
| US-20140206709-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | HPRT1, TYMP, TYMS | ROCK2 3584/4885FGFR4 1353/4885KCNH2 2670/4885 |
| US-20130123289-A1 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | HPRT1, TYMP, TYMS | ROCK2 3584/4885FGFR4 1353/4885KCNH2 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.